---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089566"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:03:15.397829+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma Q2 2023: cash $87.6M, NDA for etripamil due Oct 2023

## Summary
- Cash, equivalents & short-term investments of $87.6M; runway into mid-2025.
- NDA submission for etripamil nasal spray (PSVT) planned for October 2023.
- Enrollment complete in Phase 2 ReVeRA trial (AFib-RVR); topline data Q4 2023.
- Operating loss Q2 2023: $16.4M vs $16.8M in Q2 2022; R&D expense down to $8.6M.
- Commercial expense rose to $3.4M in Q2 2023 from $2.2M a year earlier.

## SEC filing metadata
- accession: 0001104659-23-089566
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/tm2323072d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089566
- JSON: https://secwatch.observer/filing/0001104659-23-089566.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089566.txt

## Key facts
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported the six months ended June 30, 2023 results: net income operating loss was $31.9 million.
  - Period: the six months ended June 30, 2023
  - Net income: operating loss was $31.9 million
  - Result: reported results
  source text: For the six months ended June 30, 2023, Milestone's operating loss was $31.9 million, compared to $30.9 million in the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.